


## **LISTING OF CLAIMS**

Claims 1-11 (CANCELED)

12- (NEW) A composition comprising a combination of compound (A) of formula (I),  
5 optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof,  
and clopidogrel or a pharmaceutically acceptable salt thereof :



13- (NEW) The composition of Claim 12, wherein compound (A) has the (R) configuration.

10 **14- (NEW)** The composition of Claim 12, wherein compound (A) is in the form of a sodium salt.

**15- (NEW)** The composition of Claim 12, wherein clopidogrel is in the form of a hydrogen sulphate.

16- (NEW) A pharmaceutical composition comprising as active ingredients a combination  
15 of compound (A), optionally in the form of an optical isomer, or a pharmaceutically  
acceptable salt thereof, and clopidogrel or a pharmaceutically acceptable salt thereof, in  
combination with one or more pharmaceutically acceptable, inert excipients or carriers.

17- (NEW) A pharmaceutical composition of Claim 16, wherein compound (A) has the (R) configuration.

20 **18- (NEW)** A pharmaceutical composition of Claim 16, wherein compound (A) is in the form of a sodium salt.

**19- (NEW)** A pharmaceutical composition of Claim 16, wherein clopidogrel is in the form of a hydrogen sulphate.

**20- (NEW)** A pharmaceutical composition of Claim 16, wherein the amounts of active ingredients are in the respective ranges of from 1 to 300 mg for compound (A) and from 10 to 600 mg for clopidogrel.

**21- (NEW)** A method for treating a cardiovascular illnesses involving activation of TP receptors, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of a composition of Claim 12.

**22- (NEW)** The method of Claim 21, wherein the cardiovascular illness is selected from acute coronary syndrome, stable or unstable angina, endothelial dysfunction, vascular illnesses associated with atherosclerosis, hypertension, diabetes and heart failure.

**23- (NEW)** A method for treating or preventing a disorder of the vascular, cardiovascular, or neurovascular system or a thrombo-embolic disorder, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of a composition of Claim 12.

**22- (NEW)** The method of Claim 23, wherein the thrombo-embolic disorder is associated with atherosclerosis, auricular fibrillation and invasive surgical procedures in cardiology, neurology, vascular pathology and/or radiology.